Welcome to our dedicated page for Coupang news (Ticker: $CPNG), a resource for investors and traders seeking the latest updates and insights on Coupang stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coupang's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coupang's position in the market.
Coupang, Inc. (NYSE: CPNG) reported strong financial results for the first quarter of 2024, with net revenues reaching $7.1 billion, up 23% YoY and 28% on an FX-neutral basis. Gross profit increased 36% YoY to $1.9 billion. Operating cash flow was $2.4 billion, and free cash flow was $1.5 billion for the trailing twelve months. Product Commerce segment net revenues grew 15% YoY to $6.5 billion. Developing Offerings segment net revenues surged 337% YoY to $620 million. Adjusted EBITDA for the quarter was $281 million, with a margin of 3.9%, and adjusted EBITDA for the trailing twelve months was $1.1 billion with a margin of 4.3%
